Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

NCT07284979 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1200

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity

Interventions

DRUG: KAI-9531
DRUG: Semaglutide
DRUG: Placebo

Sponsor

Kailera